China Universal Asset Management Co. Ltd. Acquires 11,793 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

China Universal Asset Management Co. Ltd. boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 64.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 29,989 shares of the biopharmaceutical company’s stock after purchasing an additional 11,793 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Ocular Therapeutix were worth $261,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Deltec Asset Management LLC boosted its stake in Ocular Therapeutix by 9.6% in the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock valued at $17,717,000 after acquiring an additional 226,181 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Ocular Therapeutix by 1,142.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock valued at $6,031,000 after purchasing an additional 609,328 shares during the period. Vanguard Group Inc. grew its holdings in Ocular Therapeutix by 41.4% during the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 2,117,029 shares during the period. Cetera Advisors LLC increased its position in Ocular Therapeutix by 1,455.0% in the first quarter. Cetera Advisors LLC now owns 723,490 shares of the biopharmaceutical company’s stock worth $6,584,000 after buying an additional 676,963 shares during the last quarter. Finally, Banco Santander S.A. raised its stake in shares of Ocular Therapeutix by 81.3% in the second quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company’s stock valued at $2,581,000 after buying an additional 169,172 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on OCUL shares. Robert W. Baird decreased their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Scotiabank initiated coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Ocular Therapeutix Price Performance

OCUL stock opened at $11.08 on Thursday. The firm has a 50 day moving average of $9.42 and a 200-day moving average of $7.59. The firm has a market capitalization of $1.73 billion, a P/E ratio of -8.37 and a beta of 1.29. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.77. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The firm had revenue of $16.40 million during the quarter, compared to the consensus estimate of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.27) earnings per share. As a group, sell-side analysts predict that Ocular Therapeutix, Inc. will post -1.02 earnings per share for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.